Cell-ebrating the dosing of patients with jCell in a phase 2 clinical trial for RP
The latest research news from Retina UK.
Search
Search results
Slowing sight loss in stargardts: Ocugen’s gene therapy trial offers promising early results
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Taking part in the 2021 Virtual London Marathon
Caryn talks about her experience taking part in the 2021 Virtual London Marathon.
New ‘vision’ and identity sight loss charities
The collective partnership of eight of the leading charities in the sight loss sector, known for the last three years as the VI Charity Sector Partnership, has re-launched under a new identity of the ‘Vision Partnership’ with a re-invigorated purpose and new strategic focus.
TCS London Marathon 2027
Join #TeamRetinaUK at the iconic TCS London Marathon 2027 and soak up the incredible atmosphere as you run from Blackheath to The Mall finish line!
Wizz Air Milan Marathon 2026
Be a part of our 50th anniversary team at the iconic Milan Marathon 2026! Join #TeamRetinaUK and soak up the incredible atmosphere as you run through the historic Italian city.
London Landmarks Half Marathon 2026
Soak up the iconic London Landmarks Half Marathon 2026 and join #TeamRetinaUK for an incredible atmosphere as you run through the capital.
Shakespeare Marathon 2026
Run with #TeamRetinaUK at the Shakespeare Marathon 2026, during our special year of 50th anniversary events.
TCS London Marathon 2026
Be a part of our 50th anniversary team at the iconic TCS London Marathon 2026! Join #TeamRetinaUK and soak up the incredible atmosphere as you run from Blackheath to The Mall finish line!